Booming growth plus shorts didnt factor in international growth- monster money maker here.
Sentiment: Strong Buy
charts show this- don't shoot the messanger
They've been out longer than most firms and have already grabbed the big customers
what a joke
crushes last 4 qts
Briefing In Play
ZYNE is a specialty pharmaceutical co focused on developing and commercializing proprietary next-genertion synthetic cannabinoid therapeutics formulated for transdermal delivery.Investors are likely to see this as a buy opportunity, GW Pharma's (GWPH) performance is up over ~1000% since listing in the US.
thats all folks
bought $ BLUE in $80's sold at $150, made a killing this looks better